Since the Gaza ceasefire took effect on October 10, 2025, repeated announcements about an imminent 'Phase Two' have created ...
Physical Properties Testers Group Limited ("PPT" or the "Company"), a global leader in physical property test and measurement solutions, announced today the appointment of Mark Fleiner as its new ...
HALIFAX, England, January 12, 2026--(BUSINESS WIRE)--Physical Properties Testers Group Limited ("PPT" or the "Company"), a global leader in physical property test and measurement solutions, announced ...
Hosted on MSN
Disney Marvel Studios phase 4 CinemaCon presentation | Full breakdown of what to expect
DISNEY MARVEL STUDIOS PHASE 4 CinemaCon Presentation | Full Breakdown Of What To Expect | WandaVision, The Eternals Footage, Shang-Chi, Black Widow, Doctor Strange 2, X-men, New Mutants, Blade, ...
Good morning, and welcome to the Transgene conference call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Transgene website following ...
Psychology Programme, School of Humanities and Behavioural Sciences, Singapore University of Social Sciences, Singapore, Singapore As higher education increasingly transitions to online platforms such ...
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows ...
MUMBAI, India and NAPLES, Fla. and BERLIN, Oct. 13, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) will present data ...
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial ZUG, Switzerland, ...
SAN FRANCISCO, Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy of ...
EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. The expansion cohort for pancreatic ductal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results